Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.45 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.45 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363326 | 1.00 | CYP19A1 (0.49) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 | |
| SCHEMBL3363331 | 1.00 | CYP19A1 (0.49) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 | |
| SCHEMBL3708014 | 1.00 | CYP19A1 (0.49) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 | |
| SCHEMBL3710947 | 1.00 | CYP19A1 (0.49) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 | |
| SCHEMBL5447445 | 0.92 | GPBAR1 (0.51) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 | |
| SCHEMBL3636500 | 0.88 | CYP19A1 (0.48) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 | |
| SCHEMBL1331512 | 0.86 | CYP19A1 (0.47) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 | |
| SCHEMBL11520209 | 0.86 | CYP19A1 (0.47) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 | |
| SCHEMBL9623704 | 0.85 | CYP19A1 (0.46) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 | |
| SCHEMBL9623701 | 0.85 | CYP19A1 (0.46) | CYP19A1AKR1B10AKR1B1EFNA1EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083655-B1 | A PROCESS FOR THE PRODUCTION OF 19-NORPREGN-4-EN-3,20-DIONE-17.ALPHA.-OL (GESTONORONE) AND INTERMEDIATES THEREFOR. | RICHTER GEDEON NYRT (HU) | 2018-02-07 | — | — | EP | disclosed |
| US-9562067-B2 | Process for the production of 19-norpregn-4-en-3,20-dione-17α-ol(gestonorone) and intermediates therefor | RICHTER GEDEON NYRT. (HU) | 2017-02-07 | — | — | US | disclosed |
| US-20160297848-A1 | A PROCESS FOR THE PRODUCTION OF 19-NORPREGN-4-EN-3,20-DIONE-17ALPHA-OL(GESTONORONE) AND INTERMEDIATES THEREFOR | RICHTER GEDEON NYRT. (HU) | 2016-10-13 | — | — | US | disclosed |
| WO-2015075693-A1 | PROCESS FOR THE SYNTHESIS OF (11 BETA.17ALPHA)-17-ACETOXY-1 1 -METHYL-19-NORPREGN-4-EN-3.20-DIONE | RICHTER GEDEON NYRT. (HU) | 2015-05-28 | — | — | WO | disclosed |
| US-20070111973-A1 | TREATMENT OF TUMOURS | HAGSTROM TOMAS | 2007-05-17 | — | — | US | disclosed |
| US-20050192262-A1 | Treatment of tumours | HAGSTROM, TOMAS (SE) | 2005-09-01 | — | — | US | disclosed |
| US-5093502-A | 14α,17α-dihydroxy-17β-substituted steroids | AKZO N.V. (NL) | 1992-03-03 | — | — | US | disclosed |
| EP-0189951-B1 | NEW PROCESS FOR THE PREPARATION OF CERTAIN STEROIDS, ESPECIALLY INTERMEDIATES FOR THE PREPARATION OF PROLIGESTONE AND RELATED COMPOUNDS, AND NEW INTERMEDIATES FORMED IN THIS PROCESS | AKZO N.V. (NL) | 1989-09-20 | — | — | EP | disclosed |
| US-4831131-A | 11β,17α-Dihydroxy-17β-cyano-androstanes | THE UPJOHN COMPANY (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0189951-A1 | New process for the preparation of certain steroids, especially intermediates for the preparation of proligestone and related compounds, and new intermediates formed in this process | AKZO N.V. (NL) | 1986-08-06 | — | — | EP | disclosed |
| EP-0188010-A1 | New process for the preparation of certain steroids, especially intermediates for the preparation of proligestone and related compounds, and new intermediates formed in this process | GIST-BROCADES N.V. (NL) | 1986-07-23 | — | — | EP | disclosed |
| US-4585590-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| US-4548748-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
| US-4500461-A | Cyanohydrin process | THE UPJOHN COMPANY (US) | 1985-02-19 | — | — | US | disclosed |
| US-4154748-A | Phosphate catalyzed acylation of steroidal tertiary alcohols | THE UPJOHN COMPANY (US) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192262-A1 | Treatment of tumours | SULT2A1, SULT1A1, HSD17B11 | CYP19A1 20/4885AKR1B10 237/4885AKR1B1 82/4885 |
| US-20070111973-A1 | TREATMENT OF TUMOURS | SULT2A1, SULT1A1, SULT1E1 | CYP19A1 24/4885AKR1B10 286/4885AKR1B1 107/4885 |
| US-20160297848-A1 | A PROCESS FOR THE PRODUCTION OF 19-NORPREGN-4-EN-3,20-DIONE-17ALPHA-OL(GESTONORONE) AND INTERMEDIATES THEREFOR | HSD17B11, CYP19A1, NR5A1 | CYP19A1 2/4885AKR1B10 246/4885AKR1B1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.